DDX43基因与肿瘤

国际肿瘤学杂志››2015,Vol. 42››Issue (2): 115-117.doi:10.3760/cma.j.issn.1673-422X.2015.02.009

陈芹,林江,钱军

212002 镇江，江苏大学附属人民医院中心实验室

出版日期:2015-02-08发布日期:2015-02-02
通讯作者:钱军 E-mail:qianjun0007@sina.com
基金资助:

国家自然科学基金(81172592、81270630)；江苏省“333工程”科研项目（BRA2013136）；镇江市科技支撑社会发展项目（SH2013082）；江苏大学2012年度医学临床科技发展基金（JLY20120011、JLY20120013）；镇江市医学重点人才项目

DDX43 gene and tumors

Chen Qin, Lin Jiang, Qian Jun

Laboratory Center, Jiangsu University Affiliated People′s Hospital, Zhenjiang 212002, China

Online:2015-02-08Published:2015-02-02
Contact:Qian Jun E-mail:qianjun0007@sina.com

摘要/Abstract

摘要：DEAD盒多肽43（DDX43）基因在肿瘤细胞恶性增殖、肿瘤细胞耐药及肿瘤免疫治疗方面发挥着重要作用。DDX43基因在多种实体瘤和某些血液系统恶性肿瘤中表达增高。DDX43基因启动子低甲基化出现于慢性髓系白血病、急性髓系白血病和骨髓增生异常综合征，并且与DDX43高表达和疾病的预后相关。

陈芹,林江,钱军. DDX43基因与肿瘤[J]. 国际肿瘤学杂志, 2015, 42(2): 115-117.

Chen Qin, Lin Jiang, Qian Jun. DDX43 gene and tumors[J]. Journal of International Oncology, 2015, 42(2): 115-117.

［1］ Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumorspecific expression［J］. Cancer Res, 2000, 60(14): 3848-3855. ［2］ Mathieu MG, Linley AJ, Reeder SP, et al. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers［J］. Cancer Immun, 2010, 10: 2. ［3］ Mathieu MG, Knights AJ, Pawelec G, et al. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class Ⅰ/Ⅱ HAGEderived immunogenic peptides［J］. Cancer Immunol Immunother, 2007, 56(12): 1885-1895. ［4］ Cordin O, Banroques J, Tanner NK, et al. The DEAD box protein family of RNA helicases［J］. Gene, 2006, 367: 17-37. ［5］ Linley AJ, Mathieu MG, Miles AK, et al. The helicase HAGE expressed by malignant melanomainitiating cells is required for tumor cell proliferation in vivo［J］. J Biol Chem, 2012, 287(17): 13633-13643. ［6］ Mathieu MG, Miles AK, Ahmad M, et al. The helicase HAGE prevents interferonainduced PML expression in ABCB5+ malignant melanomainitiating cells by promoting the expression of SOCS1［J］. Cell Death Dis, 2014, 5: e1061. ［7］ Ambrosini G, Khanin R, Carvajal RD, et al. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS upregulation in uveal melanoma cells［J］. Mol Cancer Ther, 2014, 13(8): 2073-2080. ［8］ Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer［J］. Nat Rev Cancer, 2005, 5(8): 615-625. ［9］ Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy［J］. Cancer Sci, 2009, 100(11): 2014-2021. ［10］ Riley CL, Mathieu MG, Clark RE, et al. Tumour antigentargeted immunotherapy for chronic myeloid leukaemia: is it still viable?［J］. Cancer Immunol Immunother, 2009, 58(9): 1489-1499. ［11］ Nagel H, Laskawi R, Eiffert H, et al. Analysis of the tumour suppressor genes, FHIT and WT1, and the tumour rejection genes, BAGE, GAGE1/2, HAGE, MAGE1, and MAGE3, in benign and malignant neoplasms of the salivary glands［J］. Mol Pathol, 2003, 56(4): 226-231. ［12］ Adams SP, Sahota SS, Mijovic A, et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias［J］. Leukemia, 2002, 16(11): 2238-2242. ［13］ Condomines M, Hose D, Raynaud P, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis［J］. J Immunol, 2007, 178(5): 3307-3315. ［14］ Liggins AP, Lim SH, Soilleux EJ, et al. A panel of cancertestis genes exhibiting broadspectrum expression in haematological malignancies［J］. Cancer Immun, 2010, 10: 8. ［15］ Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary［J］. Cancer Immun, 2004, 4: 1. ［16］ Akiyama Y, Komiyama M, Miyata H, et al. Novel cancertestis antigen expression on glioma cell lines derived from highgrade glioma patients［J］. Oncol Rep, 2014, 31(4): 1683-1690. ［17］ AbdelFatah TM, McArdle SE, Johnson C, et al. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer［J］. Br J Cancer, 2014, 110(10): 2450-2461. ［18］ Shen L, Kondo Y, Guo Y, et al. Genomewide profiling of DNA methylation　reveals a class of normally methylated CpG island promoters［J］. PLoS Genet, 2007, 3(10): 2023-2036. ［19］ RomanGomez J, JimenezVelasco A, Agirre X, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia［J］. Haematologica, 2007, 92(2): 153-162. ［20］ Chen Q, Lin J, Qian J, et al. The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia［J］. Genet Test Mol Biomarkers, 2013, 17(6): 508-511. ［21］ Chen Q, Lin J, Yao DM, et al. Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome［J］. Br J Haematol, 2012, 158(2): 293-296. ［22］ Lin J, Chen Q, Yang J, et al. DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia［J］. Leuk Res, 2014, 38(5): 601-607.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.